- Pembrolizumab offers better long-term survival than docetaxel in patients with previously treated, programmed death-ligand 1 (PD-L1)-expressing advanced NSCLC.
Why this matters
- Objective response rate (ORR) after 2 years was high, and second-course treatment after disease progression yielded good disease control.
- Multicenter, randomized, open-label KEYNOTE-010 trial.
- 1033 patients with previously treated PD-L1-expressing advanced NSCLC received up to 35 cycles/2 years of pembrolizumab (n=344 at 2 mg/kg and n=346 at 10 mg/kg) every 3 weeks or docetaxel 75 mg/m2 every 3 weeks (n=343).
- Median follow-up of 42.6 months.
- Funding: MSD.
- Lower mortality risk with pembrolizumab vs docetaxel:
- PD-L1 TPS ≥50%: HR, 0.53 (P<.00001>
- PD-L1 TPS ≥1%: HR, 0.69 (P<.00001>
- PD-L1 TPS ≥50%: HR, 0.57 (P<.00001>
- PD-L1 TPS ≥1%: HR, 0.83 (P=.005).
- 5 completed 17 cycles.
- 42.9% had partial response.
- 35.7% had stable disease.
- Patients with EGFR/ALK mutations were underrepresented.